C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab
C4 Therapeutics (NASDAQ:CCCC) outlined near-term clinical plans for its targeted protein degradation pipeline during a presentation at Barclays' 28th Annual Global Healthcare Conference, highlighting...